Has Heze Pharmaceutical been listed successfully?

Heze Pharmaceutical Company was listed successfully. The specific name of Heze Pharmaceutical Co., Ltd. is Zhejiang Heze Pharmaceutical Technology Co., Ltd. Heze Pharmaceutical applied for listing on the Science and Technology Innovation Board and was accepted by the Shanghai Stock Exchange on June 25th, 2002/KLOC-0. The company plans to issue no more than16.67 million shares, and it is estimated to raise 543 million yuan. Benefiting from the rapid development of domestic pharmaceutical contract service outsourcing industry, Heze Pharmaceutical has achieved rapid revenue growth in the past three years, and its net profit returned to its mother has continued to expand.

I. Overview of Heze Pharmaceutical Company

Zhejiang Pharmaceutical Technology Co., Ltd. is a service platform company focusing on drug research and development, drug certification and transformation. The company has strong and skilled R&D personnel and accumulated rich experience in project development. The company is a national high-tech enterprise with a strong R&D team and rich experience in project development. The company is also a practitioner of licensed MAH drug transformation research. Established a complete set of licensed MAH drug quality management system and project operation management system, and has the first domestic drug research and development institution "Drug Production License".

Second, Heze Pharmaceutical went public

Heze Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Heze Pharmaceutical") has signed a listing counseling agreement with Minsheng Securities, which has been filed with Zhejiang Securities Regulatory Bureau and listed in science and technology innovation board. Up to now, Heze has completed two rounds of financing, and just obtained strategic investment from Yunfeng Fund in September this year. 20 16 also completed a round of financing. The funders include Hangzhou Economic Development Zone Venture Capital, Yonghua Investment and Haibang Investment, but the amount of funds raised was not disclosed.

To sum up, Heze Pharmaceutical has built a pharmaceutical MAH license conversion platform for biomedical enterprises at home and abroad, with MAH license as the core and running through CRO R&; D CMO production, CSO sales and CSP promote the whole industrial chain, and promote the sustainable development of China MAH license "horizontal integration and vertical chain integration".